BLACK BOX WARNING
- increased risk of death, myocardial infarction, stroke, DVT, tumor progression — do NOT target Hgb >11 g/dL
- shorten overall survival and/or time-to-tumor progression in cancer patients
- use lowest effective dose
epoetin alfa
Brand: Epogen, Procrit, Retacrit (biosimilar)
⚠ BBW Prototype Drug
Drug Class: erythropoiesis-stimulating agent (ESA)
Drug Family: hematopoietic agent
Subclass: recombinant human erythropoietin
Organ Systems: hematology-oncology
Mechanism of Action
Recombinant human erythropoietin; binds and activates EpoR on erythroid progenitor cells (BFU-E, CFU-E) in bone marrow, stimulating proliferation, differentiation, and survival; increases RBC production and hemoglobin concentration over 2–4 weeks.
erythropoietin receptor (EpoR) on erythroid progenitors
Indications
- anemia of chronic kidney disease (dialysis and non-dialysis dependent)
- anemia due to chemotherapy in non-myeloid malignancies
- anemia in HIV patients on AZT
- pre-surgical autologous blood donation
Contraindications
- epoetin alfa hypersensitivity
- uncontrolled hypertension
- pure red cell aplasia (PRCA) from prior ESA exposure
Adverse Effects
Common
- hypertension (most common; can be severe)
- headache
- arthralgia
- injection site reactions
Serious
- thromboembolic events (DVT, PE, stroke, MI — especially when Hgb exceeds 11 g/dL)
- pure red cell aplasia (rare — antibody-mediated)
- tumor progression (in cancer patients)
- worsening hypertension/hypertensive encephalopathy
Pharmacokinetics (ADME)
| Absorption | SC or IV; SC bioavailability ~20–25% |
| Distribution | volume of distribution approximately equal to plasma volume |
| Metabolism | proteolytic degradation |
| Excretion | receptor-mediated; minor renal |
| Half-life | 4–13 hours (IV); 24 hours (SC) |
| Onset | 2–6 weeks (hemoglobin increase) |
| Peak | 5–24 hours (SC) |
| Duration | 3 times weekly (CKD) or weekly (cancer) |
| Protein Binding | minimal |
| Vd | low |
Drug Interactions
| Drug / Agent | Mechanism | Severity |
|---|---|---|
| iron deficiency | ESA response requires adequate iron stores; assess and supplement iron before initiating | major |
Nursing Considerations
- Do NOT target hemoglobin above 11 g/dL (CKD) or 10 g/dL (cancer) — increases risk of cardiovascular events; withhold dose when Hgb approaches 11 g/dL in CKD patients.
- Assess and correct iron deficiency (transferrin saturation <20%, ferritin <100 ng/mL) before and during therapy — ESA response requires adequate iron substrate.
- Monitor blood pressure every visit; hypertension is the most common adverse effect and may require initiation or intensification of antihypertensives.
- Cancer patients require REMS enrollment (ESAs are subject to a REMS for the cancer indication); prescribers must counsel patients on the risks.
Clinical Pearls
- Clinical trials showing excess mortality and tumor progression in cancer patients when ESAs targeted Hgb >12 g/dL led to the current restrictive use guidelines; ESAs should only be used in cancer patients with chemotherapy-induced anemia and only to avoid transfusion (not to achieve normal Hgb).
- Iron deficiency is the most common cause of ESA hyporesponsiveness; patients not responding appropriately to ESA therapy should have functional iron deficiency assessed (high ferritin but low transferrin saturation — a functional rather than absolute iron deficiency).
Safety Profile
Pregnancy use-with-caution
Lactation use-with-caution
Renal Adjustment Not required
Hepatic Adjustment Not required
TDM Not required
Guideline Update pending
Concordance Terms
Cross-referenced clinical concepts — click any term to see all content where it appears.